Loading…
the sparker alert will let you know when a significant move starts with an audio alert, so You'll never miss an Opportunity.
Geron Corp Is A Biopharmaceutical Company Focused On Blood Cancers. Its Telomerase Inhibitor, Rytelo (Imetelstat), Is Approved In The United States And European Union For Certain Adult Patients With Lower-Risk Myelodysplastic Syndromes (Lr-Mds) With Transfusion-Dependent Anemia. Rytelo Inhibits Telomerase Activity In Malignant Stem And Progenitor Cells, Which May Reduce Abnormal Cell Proliferation While Supporting The Production Of Healthy Cells. It Is Also Conducting A Phase 3 Trial Of Imetelstat In Patients With Jak-Inhibitor-Refractory Or Relapsed Myelofibrosis (R/R Mf) And Studies In Other Hematologic Malignancies. The Company Operates As A Single Segment, Being The Development Of Therapeutic Products For Oncology.